Literature DB >> 25549121

Apolipoprotein L1: from obscurity to consistency to controversy.

Michael S Lipkowitz1.   

Abstract

Apolipoprotein L1 (APOL1) is associated with increased incidence of chronic kidney disease (CKD) and end-stage renal disease, and with faster progression of CKD, in African Americans. APOL1 is expressed in intra- and extrarenal vascular tissue, making it a candidate to explain the increased incidence of cardiovascular disease in CKD. This Commentary discusses the disparate results from three studies showing that APOL1 renal risk genotypes are either harmful, neutral, or protective in the context of cardiovascular disease.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25549121     DOI： 10.1038/ki.2014.319

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  7 in total

1.  How complicated can it be? The link between APOL1 risk variants and lipoprotein heterogeneity in kidney and cardiovascular diseases.

Authors:  Chien-An A Hu; Patricio E Ray
Journal:  Nephrol Dial Transplant       Date:  2015-10-03       Impact factor: 5.992

2.  APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.

Authors:  Lijun Ma; Carl D Langefeld; Mary E Comeau; Jason A Bonomo; Michael V Rocco; John M Burkart; Jasmin Divers; Nicholette D Palmer; Pamela J Hicks; Donald W Bowden; Janice P Lea; Jenna O Krisher; Margo J Clay; Barry I Freedman
Journal:  Kidney Int       Date:  2016-05-06       Impact factor: 10.612

Review 3.  The Apolipoprotein L1 Gene and Cardiovascular Disease.

Authors:  Todd W Robinson; Barry I Freedman
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

4.  APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume.

Authors:  Barry I Freedman; Crystal A Gadegbeku; R Nick Bryan; Nicholas M Pajewski; Jasmin Divers; Nicholette D Palmer; Pamela J Hicks; Lijun Ma; Michael V Rocco; S Carrie Smith; Jianzhao Xu; Christopher T Whitlow; Benjamin C Wagner; Carl D Langefeld; Amret T Hawfield; Jeffrey T Bates; Alan J Lerner; Dominic S Raj; Mohammad S Sadaghiani; Robert D Toto; Jackson T Wright; Donald W Bowden; Jeff D Williamson; Kaycee M Sink; Joseph A Maldjian
Journal:  Kidney Int       Date:  2016-06-22       Impact factor: 10.612

5.  APOL1 Genotype and Glomerular and Tubular Kidney Injury in Women With HIV.

Authors:  Vasantha Jotwani; Michael G Shlipak; Rebecca Scherzer; Rulan S Parekh; W H Linda Kao; Michael Bennett; Mardge H Cohen; Marek Nowicki; Anjali Sharma; Mary Young; Phyllis C Tien; Chirag R Parikh; Michelle M Estrella
Journal:  Am J Kidney Dis       Date:  2015-04-24       Impact factor: 8.860

Review 6.  APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter.

Authors:  Nicholas O McLean; Todd W Robinson; Barry I Freedman
Journal:  Am J Kidney Dis       Date:  2017-01-28       Impact factor: 11.072

7.  Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients.

Authors:  Ashira Blazer; Binhuan Wang; Danny Simpson; Tomas Kirchhoff; Sean Heffron; Robert M Clancy; Adriana Heguy; Karina Ray; Matija Snuderl; Jill P Buyon
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.